Evidence map›Paper›PMID 34319235›Full record

ArticleJMIR research protocols2021

Remote Assessment of Lung Disease and Impact on Physical and Mental Health (RALPMH): Protocol for a Prospective Observational Study.

Yatharth Ranjan, Malik Althobiani, Joseph Jacob, Michele Orini, Richard Jb Dobson, Joanna Porter, John Hurst, Amos A Folarin

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in JMIR research protocols, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05630599 (Remote Assessment of Lung Disease and Impact on Physical and Mental Health), which is not on this map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05630599 unknown statusnot on this map

Remote Assessment of Lung Disease and Impact on Physical and Mental Health

TypeobservationalSponsorUniversity College, LondonRan2021 to 2023Enrolled60ConditionsChronic Obstructive Pulmonary Disease, Interstitial Lung Disease, Covid19
3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Yatharth RanjanDepartment of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.ORCID https://orcid.org/0000-0003-3079-3120
Malik AlthobianiRoyal Free Campus, University College London Respiratory, University College London, London, United Kingdom.ORCID https://orcid.org/0000-0002-2230-5708
Joseph JacobDepartment of Radiology, University College London Hospital, London, United Kingdom.ORCID https://orcid.org/0000-0002-8054-2293
Michele OriniBarts Health NHS Trust, London, United Kingdom.ORCID https://orcid.org/0000-0001-5773-0344
Richard Jb DobsonDepartment of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.ORCID https://orcid.org/0000-0003-4224-9245
Joanna PorterRespiratory Medicine, Division of Medicine, Faculty of Medical Sciences, University College London, London, United Kingdom.ORCID https://orcid.org/0000-0002-7307-169X
John HurstRoyal Free Campus, University College London Respiratory, University College London, London, United Kingdom.ORCID https://orcid.org/0000-0002-7246-6040
Amos A FolarinDepartment of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.ORCID https://orcid.org/0000-0002-0333-1927
King's College London · GBThe Royal Free Hospital · GBBarts Health NHS Trust · GBFaculty (United Kingdom) · GBUniversity College Hospital · GB

Funding

Medical Research Council MC_PC_17214Medical Research Council MR/K004158/1Wellcome Trust 209553/Z/17/Z
6 · The paper itself

Abstract

backgroundChronic lung disorders like chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF) are characterized by exacerbations. They are unpleasant for patients and sometimes severe enough to cause hospital admission and death. Moreover, due to the COVID-19 pandemic, vulnerable populations with these disorders are at high risk, and their routine care cannot be done properly. Remote monitoring offers a low cost and safe solution for gaining visibility into the health of people in their daily lives, making it useful for vulnerable populations.

objectiveThe primary objective is to assess the feasibility and acceptability of remote monitoring using wearables and mobile phones in patients with pulmonary diseases. The secondary objective is to provide power calculations for future studies centered around understanding the number of exacerbations according to sample size and duration.

methodsTwenty participants will be recruited in each of three cohorts (COPD, IPF, and posthospitalization COVID). Data collection will be done remotely using the RADAR-Base (Remote Assessment of Disease And Relapse) mobile health (mHealth) platform for different devices, including Garmin wearable devices and smart spirometers, mobile app questionnaires, surveys, and finger pulse oximeters. Passive data include wearable-derived continuous heart rate, oxygen saturation, respiration rate, activity, and sleep. Active data include disease-specific patient-reported outcome measures, mental health questionnaires, and symptom tracking to track disease trajectory. Analyses will assess the feasibility of lung disorder remote monitoring (including data quality, data completeness, system usability, and system acceptability). We will attempt to explore disease trajectory, patient stratification, and identification of acute clinical events such as exacerbations. A key aspect is understanding the potential of real-time data collection. We will simulate an intervention to acquire responses at the time of the event to assess model performance for exacerbation identification.

resultsThe Remote Assessment of Lung Disease and Impact on Physical and Mental Health (RALPMH) study provides a unique opportunity to assess the use of remote monitoring in the evaluation of lung disorders. The study started in the middle of June 2021. The data collection apparatus, questionnaires, and wearable integrations were setup and tested by the clinical teams prior to the start of recruitment. While recruitment is ongoing, real-time exacerbation identification models are currently being constructed. The models will be pretrained daily on data of previous days, but the inference will be run in real time.

conclusionsThe RALPMH study will provide a reference infrastructure for remote monitoring of lung diseases. It specifically involves information regarding the feasibility and acceptability of remote monitoring and the potential of real-time data collection and analysis in the context of chronic lung disorders. It will help plan and inform decisions in future studies in the area of respiratory health.

trial registrationISRCTN Registry ISRCTN16275601; https://www.isrctn.com/ISRCTN16275601. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): PRR1-10.2196/28873.

Indexed as

cardiopulmonary diseasesCOVID-19internet of thingslung diseasesmental healthmHealthmobile healthremote monitoringrespiratory healthwearables

Identifiers

PMID34319235
PMCPMC8500349
OpenAlexW3172720600

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.